Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor

Tanezumab is a monoclonal antibody against nerve growth factor (NGF). We investigated tanezumab pharmacokinetic (PK)‐NGF relationships and predicted the extent of systemic free NGF suppression with target‐mediated drug disposition (TMDD) modeling using data from three pivotal phase III interventiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Satoshi, Suzuki, Akiyuki, Nouri, Parya, Cai, Chun‐Hua, Gaitonde, Puneet, Marshall, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508499/
https://www.ncbi.nlm.nih.gov/pubmed/37470295
http://dx.doi.org/10.1002/psp4.13015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508499/
https://www.ncbi.nlm.nih.gov/pubmed/37470295
http://dx.doi.org/10.1002/psp4.13015

Ejemplares similares